Nordic Bioscience receives Letter of Support from the FDA for the CPa9-HNE biomarker in inflammatory bowel diseases

Nordic Bioscience receives Letter of Support from the FDA for the CPa9-HNE biomarker in inflammatory bowel diseases. Nordic Bioscience Canada France Germany Spain United States of America United Kingdom Denmark Norway Finland Sweden

View original content:https://www.prnewswire.co.uk/news-releases/nordic-bioscience-receives-letter-of-support-from-the-fda-for-the-cpa9-hne-biomarker-in-inflammatory-bowel-diseases-302299933.html